Cargando…

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor

BACKGROUND: TAK-063 is an inhibitor of phosphodiesterase 10A (PDE10A), an enzyme highly expressed in medium spiny neurons of the striatum. PDE10A hydrolyzes both cyclic adenosine monophosphate and cyclic guanosine monophosphate and modulates dopamine signaling downstream of receptor activation in bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macek, Thomas A, Suzuki, Kazunori, Asin, Karen, Kimura, Haruhide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Regular Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689203/ https://www.ncbi.nlm.nih.gov/pubmed/32598478 http://dx.doi.org/10.1093/ijnp/pyaa042

Ejemplares similares

Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor
por: Harada, Akina, et al.
Publicado: (2015)

Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents
por: Suzuki, Kazunori, et al.
Publicado: (2017)

S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS
por: Suzuki, Kazunori, et al.
Publicado: (2018)

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
por: Tsai, Max, et al.
Publicado: (2016)

Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
por: Birjandi, Shirin Z., et al.
Publicado: (2020)

Correction to: Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
por: Birjandi, Shirin Z., et al.
Publicado: (2020)

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events
por: Goldsmith, Paul, et al.
Publicado: (2017)

Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents
por: Harada, Akina, et al.
Publicado: (2019)

A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
por: Yurgelun-Todd, Deborah A., et al.
Publicado: (2019)

Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2022)

Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia
por: Tanaka, Maiko, et al.
Publicado: (2019)

TAK-071, a muscarinic M(1) receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys
por: Kurimoto, Emi, et al.
Publicado: (2019)

LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models
por: Baba, Rina, et al.
Publicado: (2021)

Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

Author Correction: Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

P063 Optogenetics for Obstructive Sleep Apnea
por: Knapman, F, et al.
Publicado: (2021)

O063. Moyamoya disease and headache: case report
por: Tozzi, Elisabetta, et al.
Publicado: (2015)

Post-Translational Modifications of the TAK1-TAB Complex
por: Hirata, Yusuke, et al.
Publicado: (2017)

The Emerging Role of Phosphodiesterases in Movement Disorders
por: Erro, Roberto, et al.
Publicado: (2021)

SAT-063 Polymicrobial Suppurative Thyroiditis Masquerading as Thyroid Storm
por: Finn, Erin E, et al.
Publicado: (2020)

Synthesis of hydroxyethyl tetrathiatriarylmethyl radicals OX063 and OX071
por: Poncelet, Martin, et al.
Publicado: (2019)

LBODP063 The Benefits Of Using Cgm For Intravenous Insulin Therapy
por: Bublik, Evgeniya, et al.
Publicado: (2022)

Characterization of 2 Novel Phosphodiesterase 2 Inhibitors Hcyb1 and PF-05180999 on Depression- and Anxiety-Like Behavior
por: Yan, Yuqing, et al.
Publicado: (2023)

Function and Structure of Lacticaseibacillus casei GH35 β-Galactosidase LBCZ_0230 with High Hydrolytic Activity to Lacto-N-biose I and Galacto-N-biose
por: Saburi, Wataru, et al.
Publicado: (2023)

2-Amino-5-methylpyridinium picolinate 0.63-hydrate
por: Hemamalini, Madhukar, et al.
Publicado: (2010)

P063. Colloid cysts of the third ventricle: a case report
por: de Pasqua, Silvia, et al.
Publicado: (2015)

AB063. 63 cases of DCD experience in renal transplant recipients
por: Sun, Xu
Publicado: (2015)

O063 Impact of sleep deprivation on distributed team performance and cohesion
por: Greer, E, et al.
Publicado: (2022)

OC.06.3 POST-COVID-19 IRRITABLE BOWEL SYNDROME
por: Marasco, G., et al.
Publicado: (2023)

FRI063 Effectiveness Of Liraglutide In Treating Obesity And Improving Hepatic Steatosis
por: Alfadda, Assim Abdulaziz, et al.
Publicado: (2023)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease
por: Tomita, Natsumi, et al.
Publicado: (2020)

TAK1 Inhibitor Enhances the Therapeutic Treatment for Glioblastoma
por: Campolo, Michela, et al.
Publicado: (2020)

ODP063 Development and Validation of Model for Sparing Adrenal Venous Sampling in Diagnosing Unilateral Primary Aldosteronism
por: Hu, Jinbo, et al.
Publicado: (2022)

SUN-LB063 Peripheral Clock System Circadian Imbalance in Cushing's Disease
por: Soares, Vinicius, et al.
Publicado: (2019)

063 Autoimmunity and disease outcomes of COVID-19, lessons from vitiligo patients
por: Post, N., et al.
Publicado: (2022)

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
por: Brown, David, et al.
Publicado: (2019)

Phosphodiesterase type 10A inhibitor attenuates lung fibrosis by targeting myofibroblast activation
por: Li, Ya-Jun, et al.
Publicado: (2023)

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_n9n7okkj0fibcrmr9lfg9k6kph